|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bilello KS, Murin S and Matthay RA:
Epidemiology, etiology, and prevention of lung cancer. Clin Chest
Med. 23:1–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boffetta P and Nyberg F: Contribution of
environmental factors to cancer risk. Br Med Bull. 68:71–94. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Didkowska J, Manczuk M, McNeill A, Powles
J and Zatonski W: Lung cancer mortality at ages 35–54 in the
European Union: Ecological study of evolving tobacco epidemics.
BMJ. 331:189–191. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paliogiannis P, Attene F, Cossu A, Budroni
M, Cesaraccio R, Tanda F, Trignano M and Palmieri G: Lung cancer
epidemiology in North Sardinia, Italy. Multidiscip Respir Med.
8:452013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ,
Ling XL and Ma SC: The prognostic value of osteopontin expression
in non-small cell lung cancer: A meta-analysis. J Mol Histol.
45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dempke WC, Suto T and Reck M: Targeted
therapies for non-small cell lung cancer. Lung Cancer. 67:257–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer-is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Campayo M, Navarro A, Viñolas N, Diaz T,
Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M
and Marrades R: Low miR-145 and high miR-367 are associated with
unfavourable prognosis in resected nonsmall cell lung cancer. Eur
Respir J. 41:1172–1178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
20
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016.PubMed/NCBI
|
|
21
|
Rahman MA, Salajegheh A, Smith RA and Lam
AK: MicroRNA-126 suppresses proliferation of undifferentiated (BRAF
(V600E) and BRAF (WT)) thyroid carcinoma through targeting PIK3R2
gene and repressing PI3K-AKT proliferation-survival signalling
pathway. Exp Cell Res. 339:342–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng K, Liu W, Liu Y, Jiang C and Qian Q:
MicroRNA-133a suppresses colorectal cancer cell invasion by
targeting Fascin1. Oncol Lett. 9:869–874. 2015.PubMed/NCBI
|
|
23
|
Li Y, Li Y, Liu J, Fan Y, Li X, Dong M,
Liu H and Chen J: Expression levels of microRNA-145 and
microRNA-10b are associated with metastasis in non-small cell lung
cancer. Cancer Biol Ther. 17:272–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kitade Y and Akao Y: MicroRNAs and their
therapeutic potential for human diseases: microRNAs, miR-143 and
−145, function as anti-oncomirs and the application of chemically
modified miR-143 as an anti-cancer drug. J Pharmacol Sci.
114:276–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang T, Thakur A, Chen T, Yang L, Lei G,
Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell
apoptosis and inhibits metastasis by targeting BCL2L2 in non-small
cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li W and He F: Monocyte to macrophage
differentiation-associated (MMD) targeted by miR-140-5p regulates
tumor growth in non-small cell lung cancer. Biochem Biophys Res
Commun. 450:844–850. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Landi MT, Zhao Y, Rotunno M, Koshiol J,
Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola
FM, et al: MicroRNA expression differentiates histology and
predicts survival of lung cancer. Clin Cancer Res. 16:430–441.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Izzotti A, Calin GA, Arrigo P, Steele VE,
Croce CM and De Flora S: Downregulation of microRNA expression in
the lungs of rats exposed to cigarette smoke. FASEB J. 23:806–812.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L,
Zeng Y, Miao R, Jin G, Ma H, et al: Genetic variants of miRNA
sequences and non-small cell lung cancer survival. J Clin Invest.
118:2600–2608. 2008.PubMed/NCBI
|
|
34
|
Ma G, Zhang F, Dong X, Wang X and Ren Y:
Low expression of microRNA-202 is associated with the metastasis of
esophageal squamous cell carcinoma. Exp Ther Med. 11:951–956.
2016.PubMed/NCBI
|
|
35
|
Shen X, Guo Y, Yu J, Qi J, Shi W, Wu X, Ni
H and Ju S: miRNA-202 in bone marrow stromal cells affects the
growth and adhesion of multiple myeloma cells by regulating B
cell-activating factor. Clin Exp Med. 16:307–316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Zheng D, Xiong Y, Xue C, Chen G,
Yan B and Ye Q: miR-202 suppresses cell proliferation in human
hepatocellular carcinoma by downregulating LRP6
post-transcriptionally. FEBS Lett. 588:1913–1920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun Z, Zhang T, Hong H, Liu Q and Zhang H:
miR-202 suppresses proliferation and induces apoptosis of
osteosarcoma cells by downregulating Gli2. Mol Cell Biochem.
397:277–283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin Z, Song D, Wei H, Yang X, Liu T, Yan W
and Xiao J: TGF-β1-induced miR-202 mediates drug resistance by
inhibiting apoptosis in human osteosarcoma. J Cancer Res Clin
Oncol. 142:239–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Meng X, Chen X, Lu P, Ma W, Yue D, Song L
and Fan Q: MicroRNA-202 inhibits tumor progression by targeting
LAMA1 in esophageal squamous cell carcinoma. Biochem Biophys Res
Commun. 473:821–827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang D, Li Y, Tian J, Zhang H and Wang S:
miR-202 promotes endometriosis by regulating SOX6 expression. Int J
Clin Exp Med. 8:17757–17764. 2015.PubMed/NCBI
|
|
41
|
Wagner KU and Schmidt JW: The two faces of
Janus kinases and their respective STATs in mammary gland
development and cancer. J Carcinog. 10:322011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Z, Ma J and Zhang L: STAT3 and
ras-MAPK signal transduction pathway in non-small cell lung cancer.
Zhongguo Fei Ai Za Zhi. 8:23–27. 2005.(In Chinese). PubMed/NCBI
|
|
43
|
Hu FY, Wang LP, Hou LL, Yin G and Wang HC:
The expressions of STAT3, WWOX and c-myc in human non small cell
lung cancer tissue and correlativity analysis. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 26:1203–1205. 1209.2010.(In Chinese).
|
|
44
|
Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang
X: Prognostic significance of STAT3 expression and its correlation
with chemoresistance of non-small cell lung cancer cells. Acta
Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu BR, Cai JM, Tang GS, Li BL, Gao F, Cui
JG and Liu HC: Effects of STAT3 antisense oligonucleotide on
proliferation and apoptosis of non-small cell lung cancer cell line
A549. Ai Zheng. 26:820–827. 2007.(In Chinese). PubMed/NCBI
|
|
46
|
Fofaria NM and Srivastava SK: STAT3
induces anoikis resistance, promotes cell invasion and metastatic
potential in pancreatic cancer cells. Carcinogenesis. 36:142–150.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dai L, Cheng L, Zhang X, Jiang Q, Zhang S,
Wang S, Li Y, Chen X, DU T, Yang Y, et al: Plasmid-based
STAT3-siRNA efficiently inhibits breast tumor growth and metastasis
in mice. Neoplasma. 58:538–547. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abdulghani J, Gu L, Dagvadorj A, Lutz J,
Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T,
et al: Stat3 promotes metastatic progression of prostate cancer. Am
J Pathol. 172:1717–1728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lin HY, Chiang CH and Hung WC: STAT3
upregulates miR-92a to inhibit RECK expression and to promote
invasiveness of lung cancer cells. Br J Cancer. 109:731–738. 2013.
View Article : Google Scholar : PubMed/NCBI
|
